Press Releases

Wipro Limited, a leading global information technology, consulting and business process services company, today announced a partnership with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI). This partnership combines Transcell’s innovative stem cell technology with the advanced augmented intelligence capabilities of Wipro HOLMES® to improve the safety of global vaccine immunization programs. By applying AI to the vaccine develop

BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed the previously announced acquisition of Stirling Ultracold ("Stirling"), a privately held manufacturer of ultra-low temperature ("ULT") mechanical freezers.  BioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding sh

HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring's plasma derived immunoglobulin administered via HCmed's new generation vibrating-mesh nebulizing device (CSL787). Under the terms of the agreement, CSL Behring will have sole responsibility for the development and commercialization of the combination product, with HCmed leading the development of the customized nebulizing device specifically

Advanced Clinical, a global clinical research services organization, is pleased to announce that the company’s global expansion into the Asia-Pacific (APAC) region continues with the opening of a new office in Singapore. Centrally located within the region, the new Singapore headquarters will function as the company’s coordination center for APAC and will serve as a key locale in close proximity to prominent Key Opinion Leaders, research centers, and current and prospect

Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced the launch of Scipher Therapeutics, focused on discovering new targets and drugs for patients not responding to existing approved therapies in the market. Scipher Medicine is leveraging its proprietary Spectra™ platform and its rich clinico-genomic data, to develop new-in-class precision therapeutics in autoimmune diseases targeting specific patient populations w

NuvOx Pharma has completed construction and initiated operation of its GMP production facility for manufacturing its injectable pharmaceutical products at its Tucson, Arizona facility. Construction of the GMP facility was financed by ImaRx Investments, LLC. The facility comprises an 1,800 square foot hard shell exterior space addition to the existing building located at 1635 East 18th Street. A 900 square foot ISO 5 cleanroom is housed within the exterior space. Olivia Longacre, Chi

Mirum Pharmaceuticals, Inc. and CANbridge Pharmaceuticals, Inc., announced today that they have entered into a licensing agreement, pursuant to which CANbridge has agreed to develop and commercialize maralixibat in Greater China (China, Hong Kong, Macau and Taiwan). Maralixibat, an investigational, orally administered medication, is being evaluated in Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Maralixibat targets the api

Burning Rock Biotech Limited announced a strategic partnership with Abbisko Therapeutics (“Abbisko”) in companion diagnostics (CDx). The two companies will work together to develop a CDx assay for ABSK091 (formerly known as AZD4547) to advance clinical research and development of the drug. The CDx assay is designed to detect FGFR genetic alterations in patients with urothelial carcinoma. ABSK091 is an innovative small molecule FGFR inhibitor, of which Abbisko has the exc

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated, announced that the FDA has granted Fast Track designation to nomacopan for the treatment of patients with moderate and severe BP. Nomacopan has also been granted orphan drug designation for nomacopan for the treatment of BP by the FDA and the European Medicines Agency (EMA). Fast trac

Silo Pharma, Inc. a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a Joint Venture with Zylo Therapeutics.  This Joint Venture will utilize Zylo’s innovative sustained release topical delivery system that was originally developed at Albert Einstein College of Medicine using Silo Pharma’s expertise in the use of psychedelics. The joint venture will initially explore the clinical develo